Patritumab (Anti-ERBB3 / HER3)

Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD.

• Supplier: Selleck Chemicals
• Product #: A2506
• Sku #: A2506-1mg